AGP Picks
View all

Hizentra market seen growing on home care and immunoglobulin demand

Nov. 4, 2026
Hizentra market seen growing on home care and immunoglobulin demand
By AI, Created 14:45 UTC, Nov 04, 2026, AGP -

The Business Research Company says the Hizentra market is gaining traction as more patients and providers shift toward subcutaneous immunoglobulin therapy, home-based care, and long-term immune disorder treatment. The report points to rising autoimmune disease rates, higher healthcare spending, and broader reimbursement support as key growth drivers through 2035.

Why it matters: - Hizentra is part of a wider shift away from hospital-based intravenous immunoglobulin therapy toward home-administered treatment. - The market’s growth matters for patients with primary immunodeficiencies and other immune-related disorders who need long-term replacement therapy. - Rising demand could improve access, convenience and dosing flexibility for patients managing chronic immune conditions.

What happened: - The Business Research Company published a new Hizentra market outlook covering market size, trends and a global forecast for 2026-2035. - The report says Hizentra demand is rising as immunoglobulin therapies evolve to meet the needs of patients with immune system deficiencies and related disorders. - The company made a free sample available in its report materials: Download a free sample of the Hizentra market report. - The company also posted the full report online: View the full Hizentra market report.

The details: - Hizentra is a subcutaneous immunoglobulin therapy used for primary immunodeficiencies such as common variable immunodeficiency, or CVID, and other immune-related disorders. - Hizentra contains immunoglobulin G, or IgG, which supports the immune system in fighting infections. - The therapy is administered beneath the skin as an alternative to intravenous immunoglobulin therapy. - The report says subcutaneous delivery can offer greater convenience, self-administration and dosing flexibility. - Historical growth has been driven by the challenges of IVIg therapy in hospital settings and by a rising number of primary immunodeficiency cases. - Future growth is expected to come from wider home healthcare access, better diagnosis rates, stronger demand for long-term replacement therapy, infusion device advances and supportive reimbursement policies for SCIg therapies. - Reported trends include a shift toward subcutaneous immunoglobulin treatment, more home-based care, flexible dosing schedules and greater focus on quality of life.

Between the lines: - The market outlook suggests Hizentra is benefiting from a broader care model change, not just product demand. - Rising autoimmune diagnoses and longer-term disease management appear to be expanding the patient pool for immunoglobulin replacement therapies. - Reimbursement and home-care infrastructure look increasingly important to adoption because they can lower barriers to treatment outside hospitals. - The report’s emphasis on quality of life signals that treatment convenience is becoming a competitive factor alongside clinical efficacy.

What's next: - The report expects the Hizentra market to keep expanding through 2035 as healthcare systems improve diagnosis and home treatment options. - Asia-Pacific is projected to be the fastest-growing region during the forecast period. - North America held the largest market share in 2025. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The Business Research Company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrices, Excel dashboards, hotspot infographics, and updated technology and trend analysis.

The bottom line: - Hizentra’s growth story is being driven by more than one factor: more patients, more home care, and more support for subcutaneous therapy.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

LATAM Technology Reporter

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

LATAM Technology Reporter

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.